Top healthcare legislation to watch so far this year

Date:

This audio is auto-generated. Please let us know if you have feedback.

This year has brought significant changes to the healthcare industry, ushered in by the Trump administration and the recently enacted “One Big Beautiful Bill Act.” Providers, insurers and health IT companies are looking ahead to Medicaid cuts, big changes to the Affordable Care Act and a reduction in funding for providers. 

But, while some major policy shifts have stemmed from executive orders or health agencies, lawmakers have been working to propose their own healthcare legislation.

Lawmakers in the House and Senate have introduced legislation aimed at reforming Medicare Advantage plans, overhauling transgender healthcare, cementing artificial intelligence in the sector, curbing some business practices of pharmacy benefit managers, equalizing payments between certain providers and more.

Some bills attempt to circumvent changes to healthcare policy made by the Trump administration, like those attempting to safeguard access to abortion and protect some ACA funding. Others try to cut government healthcare programs even further.

These are the top bills addressing core issues in healthcare this year.

340B

The 340B drug discount program was created more than three decades ago to help providers treating the most vulnerable Americans afford expensive drugs. Helping safety-net hospitals and clinics stretch scarce resources is a mission seemingly everyone can get behind. But for many critics – including drugmakers upset that 340B means lower profits and fiscal hawks concerned about snowballing spending — the program has mutated well beyond its original intent.

That’s put Congress in a bind, caught between calls to protect 340B on one side and to overhaul the program on the other. The disconnect is reflected in comments from lawmakers — but not in bills introduced this year, which would largely preserve the status quo or even grow the 340B program.

Early this year, Rep. Jack Bergman, R-Mich., reintroduced a bill with bipartisan support that would extend 340B discounts to rural emergency hospitals. And in July, Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., introduced a bill called the 340B PATIENTS Act that would shield providers’ use of contract pharmacies to dispense 340B drugs.

It’s a major point of contention in the program: Before 2010, 340B providers could only contract with one outside pharmacy. But the HHS reversed the policy, causing the number of pharmacies in 340B to skyrocket from 1,300 in 2010 to more than 30,000 in 2025.

Investigations by the Government Accountability Office and members of Congress suggest this explosion has allowed improper dispensing to run rampant. Only half of contract pharmacies pass 340B discounts along to patients, and contract pharmacies are often located in wealthier areas that shouldn’t need savings from 340B, according to the Government Accountability Office.

Meanwhile, the 340B PATIENTS Act, if passed, would conflict with several federal court rulings limiting hospitals’ use of contract pharmacies in litigation brought by drugmakers. Still, the bill has strong support from hospitals, and is in line with several states that have passed laws stopping drugmakers from restricting hospitals’ use of contract pharmacies to dispense 340B drugs.

Bills introduced last Congress, including the 340B ACCESS Act, the 340B Transparency Act and a draft bill circulated by a bipartisan working group called SUSTAIN 340B, would put more guardrails around the program. Suggested policies include requiring hospitals to more directly funnel 340B savings along to patients; creating more transparency by forcing hospitals to report 340B data, like margins on discounted drugs; and preventing the unlimited use of contract pharmacies.

Pharmacy benefit managers

Lawmakers agree that something needs to be done about pharmacy benefit managers, but it’s less clear what steps they could take.

PBM reform was cut from a spending package at the end of 2024, and a flurry of bills this year lay out diverse policies meant to prevent the drug middlemen from profiteering off of their position in the U.S. pharmaceutical supply chain.

Source link

Share post:

Subscribe

Popular

More like this
Related